ellagic acid
Ellagic acid is a dilactone of hexahydroxydiphenic acid, that found in numerous fruits and vegetables. Ellagic acid was first discovered by chemist Henri Braconnot in 1831. Ellagic acid is found in oaks species like the North American white oak (Quercus alba) and European red oak (Quercus robur). The highest levels of ellagic acid are found in walnuts, pecans, cranberries, raspberries, strawberries, and grapes, as well as distilled beverages. It is also found in peach, and other plant foods. Ellagic acid has antiproliferative and antioxidant properties in a number of in vitro and small-animal models. The antiproliferative properties of ellagic acid may be due to its ability to directly inhibit the DNA binding of certain carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons. As with other polyphenol antioxidants, ellagic acid has a chemoprotective effect in cellular models by reducing oxidative stress. Ellagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement of cardiovascular function in adolescents who are obese (phase 2 trial), and topical treatment of solar lentigines. Ellagic acid has been marketed as a dietary supplement with a range of claimed benefits against cancer, heart disease, and other medical problems. Ellagic acid has been identified by the U.S. Food and Drug Administration as a "fake cancer 'cure' consumers should avoid". — NCATS
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2003 (NCT00728299)
Timeline
Indications
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
SMILES
OC1=C(O)C2=C3C(=C1)C(=O)OC4=C3C(=CC(O)=C4O)C(=O)O2- Mol. weight
- 302.1926 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEllagic acid ↗
- NCATS19YRN3ZS9P ↗
- ChEMBLCHEMBL6246 ↗
Also known as
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
- benzoaric acid
- benzoaric acid
- ellagic acid
- ellagic acid
- ellagic acid
- ellagic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07182370 | N/A | Jan 15, 2024 | Government of Spain, Universidad de Murcia |
| NCT04011618 | Phase 2 | Sep 30, 2019 | Government of Mexico, University of Guadalajara |
| NCT03713164 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2018 | University of California, Los Angeles |
| NCT02263378 | N/A | Sep 1, 2014 | University of Messina |
| NCT00455416 | Phase 2 | Apr 1, 2007 | Osaka University, University of Oslo |
| NCT00728299 | N/A | Sep 1, 2003 | POM Wonderful LLC, Radiant Research |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Mexico | Government | 1 | 0 | 1 | 2019 |
| Government of Spain | Government | 1 | 1 | 1 | 2024 |
| Osaka University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| POM Wonderful LLC | For profit | 1 | 0 | 1 | 2003 |
| Radiant Research | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Universidad de Murcia | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Guadalajara | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Messina | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2007 |